Prof. Drew Pardoll, a Director at Compugen USA, Inc., is the Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics at Johns Hopkins University of Medicine, and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Sidney Kimmel Cancer Center, Johns Hopkins. For the past two decades, Prof. Pardoll has studied molecular aspects of immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system and has made seminal advances in immunology, including the discovery of new types of immune cells and regulatory mechanisms. He was the first to propose blockade of PD-1 for cancer therapy, and his research led the clinical development of the first anti-PD-1 antibody. Prof. Pardoll is the inventor of a number of immunotherapies, including cancer vaccines, and was a scientific founder of Amplimmune Inc. Prof. Pardoll completed his M.D., Ph.D, Medical Residency and Oncology Fellowship at Johns Hopkins University.
Prof. Drake specializes in cancer immunotherapies, focusing on immune checkpoints, and cancer vaccines. He has significant experience conducting clinical trials involving these therapies. He is Director of Genitourinary Oncology and Associate Director for Clinical Research at the Herbert Irving Comprehensive Cancer Center, at the Columbia University Medical Center (CUMC), Co-Director of Columbia’s Cancer Immunotherapy Program and on the faculty of CUMC. Dr. Drake is also a member of the Prostate Cancer Foundation Scientific Advisory Board. Dr. Drake received his Ph.D. in Immunology from the National Jewish Center for Immunology and his M.D. from the University of Colorado Health Sciences Center in Denver, Colorado.
Prof. McInnes’ major area of interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He is Muirhead Chair of Medicine and Director of Institute of Infection, Immunity and Inflammation at the University of Glasgow. He oversees a translational science program and is involved with an extensive clinical trial facility, performing studies of novel biologic agents in inflammatory arthritis. He has served as Principal Investigator for numerous clinical studies in drug development programs. Prof. McInnes studied medicine at the University of Glasgow, and trained in Ph.D. and postdoctoral studies at the National Institutes of Health in Bethesda, Maryland.
Prof. Ribas holds positions in Hematology/Oncology and Surgical Oncology at the University of California, Los Angeles (UCLA). He conducts laboratory and clinical research on novel strategies for immunotherapy of cancer, focusing on malignant melanoma, and has served as Principal Investigator for clinical studies in drug development programs. He is the Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Committee at SWOG (Southwest Oncology Group). Prof. Ribas is also a permanent committee member of the National Cancer Institute (NCI) grant review panels and an elected member of the American Society of Clinical Investigation (ASCI). He studied medicine at the University of Barcelona, Spain, and has undergone postdoctoral training at the Sidney Kimmel Cancer Center in San Diego and at UCLA.
Dr. Soule is a world leader in the identification and development of new drugs for prostate cancer. Dr. Soule is the Executive Vice President and Chief Science Officer at the Prostate Cancer Foundation, and Senior Fellow at the Milken Institute. He coordinates global academic, government and biopharmaceutical sector research activity and is responsible for the implementation of Prostate Cancer Foundation global research strategies. Dr. Soule received his Ph.D. from Baylor College of Medicine in virology and epidemiology, and was a postdoctoral fellow in immunology and vascular biology at the Scripps Research Institute. Dr. Soule has substantial R&D and business development experience in the biopharmaceutical and diagnostics industries.
Prof. Merad’s research examines the contribution of tumor infiltrating macrophages and dendritic cells to tumor progression and response to conventional and targeted therapies. She is the Director of the Precision Immunology Institute and the Co-Leader of the Cancer Immunology Immunotherapy program at The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai. Prof. Merad trained as an oncologist in France and obtained her Ph.D. in immunology at Stanford University and the University of Paris VII.